Channel Therapeutics Corporation (CHRO) Stock Overview
Explore Channel Therapeutics Corporation’s financial performance, market position, analyst ratings, and future outlook.
Channel Therapeutics Corporation (CHRO)
Key Financials
Key Financials
Market Cap
8.9M
P/E Ratio
-0.09
EPS (TTM)
$-12.00
ROE
-1.64%
CHRO Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Channel Therapeutics Corporation (CHRO) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of C+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
Our forecasting models predict significant price movements, with a 12-month target of $3.13.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.09 and a market capitalization of 8.9M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.